Nick DeAngelis

NICK DEANGELIS represents buyers and sellers in M&A transactions, as well as public and private companies and investors in fundraising transactions. Nick has represented buyers and sellers in M&A transactions in a variety of industries, most notably in the life sciences, medical device, and technology industries. He has represented public companies, including many life sciences and biotechnology companies, in public and private offerings including IPOs, underwritten offerings, registered direct offerings, PIPE offerings, and ATM offerings. Nick has also represented both companies and investors in numerous venture capital investments, and he regularly advises the directors and management of both public and private corporations on a wide variety of corporate governance matters.

Nick earned his J.D., cum laude, from the Northwestern University School of Law, where he was a senior editor of the Journal of International Law and Business. He received his bachelor’s degree, magna cum laude, from Lincoln Memorial University with a dual major in history and in philosophy and religion.

Nick’s experience includes representing:

M&A

• Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, in its acquisition of Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node therapies targeting tumor metabolism and signaling.
• Private credit investor Magnetar Capital in numerous debt and equity investment and joint venture transactions.
• ABM Industries in its acquisition of WGNSTAR, a leading provider of managed workforce and critical equipment service solutions for semiconductor fabrication and high tech manufacturing facilities, and its acquisition of Quality Uptime Services, a provider of mission critical UPS maintenance and services for data centers and critical facilities.
• Contego Medical, a medical device company, in connection with a series of related agreements with Medtronic, a strategic investment, exclusive distribution agreement and an acquisition option agreement.
• Mercury/13 in its partnership with Avenue Sports Fund, a leading global sports investment fund of Avenue Capital Group.
• Angel City Football Club in its sale to Willow Bay and Bob Iger.
• Pluto Capital, Inc. in its sale to Robinhood Markets, Inc. Pluto Capital, Inc. is an artificial intelligence (AI) powered investment research platform that delivers highly-customized investment strategies based on customer needs and financial goals.
• RenaissanceRe Holdings Ltd. in its US$2.985 billion acquisition of American International Group Inc.’s treaty reinsurance business, which includes Validus Reinsurance Ltd. and its consolidated subsidiaries, AlphaCat Managers Ltd. and its managed funds, and all renewal rights to the Assumed Reinsurance Treaty Unit of Talbot Treaty.
• Specialty Dental Brands, a dental support organization, in connection with an investment by TSG Consumer Partners, a private equity firm.
• The Arnold Companies, in the sale of its TAC Air division to Signature Aviation, the world’s largest network of fixed-base operators.
• EnterpriseDB, in its majority growth investment from Bain Capital Private Equity.
• Callodine Group in its 13e-3 take-private acquisition of investment-management firm Manning & Napier (NYSE: MN).
• Tempest Therapeutics, a privately held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, in connection with its merger with Millendo Therapeutics.
• Regal Beloit Corporation in its US$9.1 billion combination with the Process & Motion Control (PMC) Business of Rexnord Corporation.
• NuVera Medical, Inc., a medical technology company, in connection with its acquisition by Biosense Webster, a wholly owned subsidiary of Johnson & Johnson.
  Salesforce in its $1.33 billion acquisition of Vlocity, Inc.
• Shape Security, Inc. in its acquisition by F5 Networks, Inc. for $1 billion.
• Splunk Inc. on its acquisition of cloud monitoring leader SignalFX for $1.05 billion in cash and stock.
• Varian Medical’s further expansion into interventional oncology through its acquisitions of Endocare (cryoablation and microwave ablation); Alicon (embolic therapy); and the microsphere and bland embolic bead products of Boston Scientific.

Capital Markets

• Capricor Therapeutics in connection with equity financing transactions.
• Opus Genetics in connection with its US$155 million financing with Oberland Capital.
• Life360 in its upsized offering of US$275 million aggregate principal amount of convertible senior notes.
• Outset Medical, a medical technology company, on its US$169 million PIPE/private placement.
• Acrivon Therapeutics in its US$130 million private placement financing.
• RenaissanceRe Holdings Ltd. in a US$1.39 billion common stock offering (inclusive of the exercise of the green shoe) led by Morgan Stanley and Goldman Sachs.
• IO Biotech, a clinical-stage biopharmaceutical company, on its US$115.1 million initial public offering.
• Argo Blockchain, a global leader in cryptocurrency mining, on its Nasdaq IPO.
• Cambium Networks Corporation in its secondary public offering of 2.5 million ordinary shares sold by an affiliate of Vector Capital at US$28.00 per share.
• Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, on its $72 million initial public offering.
• Outset Medical, a medical technology company, on its $278 million initial public offering, its $212 million secondary public offering, and its $365.8 million follow-on offering.
• The RealReal in its $345 million initial public offering.
• Tricida, Inc. in its US$256 million initial public offering its US$57.5 million Series D Financing.

Emerging Companies and Venture Capital

• Nourish, the largest dietitian-led metabolic health clinic in the United States, in its US$100 million Series C financing and in its US$70 million Series B funding round.
• VERO Biotech, a medical technology company, in multiple preferred equity and debt financings.
• Aeris, a leading Software as a Service-based Internet of Things (IoT) provider, in its strategic investment from private equity firm TA Associates.
• Supira Medical in its US$120 million Series E financing.
• Remote-desktop-technology startup, Phaze, in its series-seed venture financing.
• Roche in its investment in Freenome, a multiomics platform based lifesciences company, with aggregate proceeds from Roche and other investors in excess of US$840 million.
• Atia Vision Inc. in its Series E financing led by Cormorant Asset Management with participation by The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed Angel investors.
• American Airlines in its investment in ZeroAvia, a leader in hydrogen-electric, zero-emission aviation.
• GIC Pte. Ltd. in its investment in Apeel Sciences, an innovative food waste reduction company.
• Audio Up Inc., in connection with the sale of Series A Preferred Stock to a group of investors led by Metro-Goldwyn-Mayer Studios (MGM) Inc.
• GlaxoSmithKline in its collaboration with and equity investment in Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients.